Aquapharm and Dundee University Sign Research Collaboration to find Marine Compounds to target Alzheimer’s
Aquapharm Biodiscovery announced it has signed a research agreement with Dundee University to help it develop new drugs based on marine natural products that may help in the fight against Alzheimer’s.
Alzheimer's is a disease marked by the formation of insoluble protein aggregates in the brain with associated progressive degeneration of the neurons. The collaboration is aimed at O-GIcNAcase, a well-documented target for Alzheimer’s, that modulates the solubility of the protein in these aggregates but that has been difficult to target with conventional small-molecule libraries. It therefore forms an ideal opportunity to demonstrate that Aquapharm’s growing collection of novel and diverse marine-derived compounds and scaffolds can modulate a clinically attractive but pharmacologically challenging target for a disease for which new solutions are urgently required.
Aquapharm will be working with Professor Daan van Aalten, Professor of Biological Chemistry at the University, who brings to the collaboration expertise in studying the structural aspects and mechanism of protein-carbohydrate interactions, and applies this knowledge to design molecules that modulate these interactions in biological systems as research tools or leads for the development of chemotherapeutics.
Aquapharm will fund research in Professor van Aalten’s labs and will provide access to extracts from Aquapharm’s culture collection of marine micro-organisms to screen and “mine” for individual active compounds. Dundee will provide knowledge transfer of the O-GlcNAcase high-throughput screens to Aquapharm to allow the company to conduct screening work to run alongside the academic programme.
Initial results from this research agreement are expected during 2011.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Nanomedicines on their way through the body - Which pathways do nanomedicines take after they have been swallowed?
Bavarian Nordic receives USD 25 million milestone payment after submission of IMVAMUNE data to the U.S. Health Authorities
Cellular contamination pathway for plutonium, other heavy elements, identified - Scientists find that an iron-binding protein can transport actinides into cells
Salmon genome in final phases of completion
Lundbeck expands the agreement with Teva to include marketing of Azilect in selected Asian countries
Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid - Two pivotal Phase III studies showed ACZ885 may meet significant unmet need for patients for whom many standard therapies are inadequate or inappropriate
Breakthrough in mapping nicotine addiction could help researchers improve treatment
Study shows how bioactive substance inhibits important receptor - Results from the University of Bonn raise hope for new drugs against cancer and brain diseases
Natural UV radiation in winter not strong enough against SARS-CoV-2 - In winter the virus has a good chance of survival outside
Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics
